Rodgers.Manual de hematología clínica_5ed

385

CAPÍTULO 22 ■ TROMBOEMBOLIA VENOSA

73. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3N-untranslated region of the pro thrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996;88:3698‐3703. 74. Dahlback B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci U S A . 1981;78:2512‐2516. 75. Zwicker J, Bauer KA. Thrombophilia. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Thrombosis and Hemo stasis . W.B. Saunders Company; 2002:181‐196. 76. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. et al. Homocysteine low ering with folic acid and B vitamins in vascular disease. N Engl J Med . 2006;354(15):1567‐1577. doi:10.1056/NEJMoa060900 77. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb . 2002;32:51‐58. 78. Kearon C, Akl EA, Comerata AJ, et al. Antithrombotic therapy for VTE disease antithrombotic therapy and preven tion of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest . 2012;141(2 Suppl):e419S‐e494S. 79. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv . 2020;4(19):4693‐4738. doi:10.1182/bloodadvances.2020001830 80. Keron C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest . 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026. Erratum in: Chest . 2016;150(4):988. 81. Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and Expert Panel Report. Chest . 2021;160(6):2247‐2259. doi:10.1016/j.chest.2021.07.056 82. Kirkilesis G, Kakkos SK, Bicknell C, Salim S, Kakavia K. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev . 2020;4(4):CD013422. doi:10.1002/14651858.CD013422.pub2 83. Sculman S, Kearon C, Kakkar AK, et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med . 2009;361:2342‐2352. 84. Schulman S, Kakkar AK, Goldhaber SZ. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation . 2014;129:764‐772. 85. Goldhaber SZ, Schellong S, Kakkar A, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost . 2016;116(4):714‐721. doi:10.1160/ TH16-04-0271 86. Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thrombo embolism. N Engl J Med . 2013;369(9):799‐808. doi:10.1056/NEJMoa1302507 87. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous throm boembolism. N Engl J Med . 2010;363(26):2499‐2510. doi:10.1056/NEJMoa1007903 88. EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med . 2012;366(14):1287-1297. doi:10.1056/NEJMoa1113572 89. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low intensity warfarin for the prevention of recurrent venous thromboembolism. N Engl J Med . 2003;348:1425‐1434. 90. Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous throm boembolism. N Engl J Med . 2013;368(8):699‐708. doi:10.1056/NEJMoa1207541 91. Weitz JI, Lensing AWA, Prins MH, et al.; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treat ment of venous thromboembolism. N Engl J Med . 2017;376(13):1211‐1222. doi:10.1056/NEJMoa1700518 92. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med . 1998;338:409‐415. 93. European Society of Cardiology: guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J . 2000;21:1301‐1336. 94. Comerota AJ. The ATTRACT Trial: rationale for early intervention for iliofemoral DVT. Perspect Vasc Surg Endovasc Ther . 2009;21:221‐225. 95. Enden T, Haig Y, Klow N-E, et al. Long-term outcome after additional catheter-directed thrombolysis versus stan dard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet . 2012;379:31‐38.

96. Vedantham S, Millward SF, Cardella JF, et al. Society of Interventional Radiology position statement: treatment of acute iliofemoral deep vein thrombosis with use of adjunctive catheter-directed intrathrombus thrombolysis. J Vasc Interv Ra diol . 2006;17:613‐616. Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.